Turnstone Biologics Corp. Common Stock
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California. As of August 11, 2025, Turnstone Biologics Corp. operates as a subsidiary of XOMA Royalty Corporation.
Turnstone Biologics Corp. Common Stock (TSBX) - Total Assets
Latest total assets as of June 2025: $21.11 Million USD
Based on the latest financial reports, Turnstone Biologics Corp. Common Stock (TSBX) holds total assets worth $21.11 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Turnstone Biologics Corp. Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how Turnstone Biologics Corp. Common Stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Turnstone Biologics Corp. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Turnstone Biologics Corp. Common Stock's total assets of $21.11 Million consist of 85.3% current assets and 14.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how Turnstone Biologics Corp. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Turnstone Biologics Corp. Common Stock's current assets represent 85.3% of total assets in 2024, a decrease from 94.7% in 2021.
- Cash Position: Cash and equivalents constituted 72.1% of total assets in 2024, up from 65.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Turnstone Biologics Corp. Common Stock Competitors by Total Assets
Key competitors of Turnstone Biologics Corp. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Turnstone Biologics Corp. Common Stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Turnstone Biologics Corp. Common Stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Turnstone Biologics Corp. Common Stock is currently not profitable relative to its asset base.
Turnstone Biologics Corp. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.33 | 4.38 | 2.81 |
| Quick Ratio | 3.33 | 4.38 | 2.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.76 Million | $ 52.77 Million | $ 63.17 Million |
Turnstone Biologics Corp. Common Stock - Advanced Valuation Insights
This section examines the relationship between Turnstone Biologics Corp. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.56 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | -64.4% |
| Total Assets | $40.14 Million |
| Market Capitalization | $5.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values Turnstone Biologics Corp. Common Stock's assets below their book value (0.12 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Turnstone Biologics Corp. Common Stock's assets decreased by 64.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Turnstone Biologics Corp. Common Stock (2021–2024)
The table below shows the annual total assets of Turnstone Biologics Corp. Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $40.14 Million | -64.42% |
| 2023-12-31 | $112.81 Million | -1.85% |
| 2022-12-31 | $114.94 Million | -38.62% |
| 2021-12-31 | $187.24 Million | -- |